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Abstract
Purpose—Many regions have implemented newborn screening (NBS) for cystic fibrosis (CF) 
using a limited panel of cystic fibrosis transmembrane regulator (CFTR) mutations after 
immunoreactive trypsinogen (IRT) analysis. We sought to assess the feasibility of further 
improving the screening using next-generation sequencing (NGS) technology.
Methods—An NGS assay was used to detect 162 CFTR mutations/variants characterized by the 
CFTR2 project. We used 67 dried blood spots (DBSs) containing 48 distinct CFTR mutations to 
validate the assay. NGS assay was retrospectively performed on 165 CF screen–positive samples 
with one CFTR mutation.
Results—The NGS assay was successfully performed using DNA isolated from DBSs, and it 
correctly detected all CFTR mutations in the validation. Among 165 screen-positive infants with 
one CFTR mutation, no additional disease-causing mutation was identified in 151 samples 
consistent with normal sweat tests. Five infants had a CF-causing mutation that was not included 
in this panel, and nine with two CF-causing mutations were identified.
Conclusion—The NGS assay was 100% concordant with traditional methods. Retrospective 
analysis results indicate an IRT/NGS screening algorithm would enable high sensitivity, better 
specificity and positive predictive value (PPV). This study lays the foundation for prospective 
studies and for introducing NGS in NBS laboratories.
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INTRODUCTION
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease among 
Caucasians, occurring in ~1 in 4,000 newborns, and is caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. Although over 1,900 CFTR 
mutations have been reported in the CF Mutation Database (http://
www.genet.sickkids.on.ca), it has recently been recognized that the majority of those 
mutations are not associated with CF.1 There has been a recent effort to rigorously ascertain 
the disease liability of CFTR mutations through a pivotal project known as CFTR2, the 
Clinical and Functional Translation of CFTR.1 The CFTR2 project initially found that 159 
CFTR variants account for 96.4% of CF alleles in their large-scale meta-analysis,1 and as of 
4 April 2014, there are reported 176 CF-causing mutations, 12 that are not CF-causing 
variants, and 11 mutations with varying clinical consequences; seven variants are still under 
evaluation (http://www.cftr2.org).
Because of growing evidence of the benefits of early diagnosis for patients with CF,2 many 
regions worldwide, including every state in the United States, have implemented routine 
newborn screening (NBS) for CF. Most CF NBS programs use a method of analyzing a 
limited number of CFTR gene mutations (typically 23–40) following an immunoreactive 
trypsinogen (IRT) analysis on dried blood spot (DBS) specimens (the two-tier IRT/DNA 
algorithm).3,4 The sensitivity of the two-tier test is largely determined by the IRT cutoff 
value chosen, but it is also influenced by the number of mutations in the CFTR panel.5 
Infants with a high IRT level and either one or two mutations detected are reported as screen 
positive and are referred for sweat testing in diagnostic evaluations. In at least 10% of cases, 
however, the sweat results are inconclusive.6 Moreover, ~90% of infants with one mutation 
have normal sweat test results and are therefore CF heterozygote carrier infants who are 
categorized as screening false positive.7 These CF NBS false-positive results can cause 
parental anxiety,8–10 add considerable expense to NBS,11 and may delay the diagnosis of CF 
when one mutation is detected9 or insufficient quantities of sweat are obtained.6 Therefore, 
the challenges associated with false positives based on carrier detection in the common 
IRT/DNA protocol are significant and magnified by the disproportionately large number of 
carriers in the population with high IRT levels.9,10 Although restricting the number of CFTR 
mutations in CFTR panels can reduce carrier detection and potentially improve the positive 
predictive value (PPV), the NBS goals of equity and the highest possible sensitivity become 
more difficult to achieve. Finally, NBS via the IRT/DNA algorithm has identified a new and 
unexpected challenge:identifying infants who do not meet the criteria for a diagnosis of CF 
but are labeled as having CFTR-related metabolic syndrome (CRMS) in the United States 
since 2009.12,13
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In a quality improvement effort intended to address the shortcomings of the current 
IRT/DNA algorithm and therefore enhance NBS for CF, we undertook a project to 
strategically evaluate expanded DNA analyses in NBS for CF targeting only CF-causing 
mutations. The NGS platform was a logical assay because of its capability to simultaneous 
detect a large number of mutations in a scalable manner with the turnaround time required in 
a NBS laboratory setting.14 Specifically, we used the investigator-use-only (IUO) version of 
a CF assay that was designed to detect simultaneously a panel of 162 CFTR mutations/
variants for which clinical consequences have been described in the CFTR2 project. Here 
we report our experience of validating this NGS method using 67 DBS samples with 48 
distinct, known CFTR mutations. We assessed the robustness of the assay using a 
laboratory-developed simple DNA isolation method with DBS specimens to demonstrate the 
feasibility of introducing NGS into high-throughput NBS laboratories with a fast-paced 
routine. In addition, in a retrospective study designed to assess the potential applicability of 
an IRT/NGS algorithm to Wisconsin NBS for CF, we performed this NGS assay on 165 
residual NBS-positive specimens that were identified with only one of 23 CFTR mutations 
recommended by the American College of Medical Genetics and Genomics,15 the panel 
currently used for NBS in Wisconsin.7
MATERIALS AND METHODS
Study cohort and DBS specimens
A total of 67 DBS specimens were used to verify and validate the assay: 44 de-identified 
residual NBS specimens with two CFTR mutations identified through NBS or a clinical 
confirmatory testing process, and 23 CF proficiency testing samples from the Newborn 
Screening and Molecular Biology Branch at the Centers for Disease Control and Prevention 
(CDC).16 Those 67 DBS specimens contained 48 distinct CFTR mutations included in the 
162-mutation/variant NGS panel. The status of poly-T and TG repeats in intron nine was 
known for nine Wisconsin samples and all 23 samples provided by the CDC.
From 1 June 2012 to 31 May 2013, Wisconsin screened 61,257 newborns for CF using the 
two-tier IRT/DNA algorithm. Specimens within the top 4% of the daily IRT values were 
tested for the American College of Medical Genetics and Genomics panel of 23 CFTR 
mutations, and the infants with one or more CFTR mutations detected were considered 
screen-positive for CF (n = 8 with two CFTR mutations, n = 184 with one CFTR mutation). 
Among the group with one mutation, 165 specimens had sweat test results and/or clinical 
assessment available. Those specimens were de-identified and used in this analysis by both 
the University of Wisconsin and CDC. All NGS assay results were compared with the sweat 
test results and/or clinical outcomes for concordance. This study was approved by the Health 
Sciences Institutional Review Board at the University of Wisconsin–Madison as not 
constituting research as defined under 45 CFR 46.102(d). The CDC's Office of Science at 
the National Center for Environmental Health determined the CDC's involvement as not 
involving identifiable human subjects under 45 CFR 66.012(d).
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Each DNA sample was isolated from a 3.2-mm DBS punch in Generation DNA Purification 
Solution and Elution Solution (Qiagen, Valencia, CA) using manufacturer-recommended 
wash steps with some modifications. DNA then was eluted in 24 μl of molecular-grade 
water and incubated at 99 °C for 25 minutes.17 DNA also was isolated using a laboratory-
developed, one-step method. Each 3.2-mm DBS punch was incubated with 54 μl of DNA 
elution buffer (5 mmol/l potassium hydroxide, 7.5 mmol/l potassium chloride, and 15 
mmol/l Tris-base at 95 °C for 25 minutes. Both methods used 5 μl of isolated DNA for the 
NGS assay.
NGS assay for detection of CFTR mutations/variants
CFTR mutations are described using both the international nomenclature of the Human 
Genome Variation Society (http://www.hgvs.org/mutnomen/) and legacy mutation 
nomenclature (http://www.cftr2.org/browse.php). The assay consisted of the Illumina 
MiSeqDx IUO CF assay system (Illumina, San Diego, CA), which includes reagents to 
sequence the full coding region and intron/exon boundaries of the CFTR gene from genomic 
DNA samples. The MiSeq Reporter data analysis masks sequence data to reveal the status of 
only the 162 mutations/variants in the CFTR gene characterized by the CFTR2 project, 
including 127 single-nucleotide substitution mutation/variants, 32 insertion/deletion 
mutations, exon 2–3 and exon 22–23 deletions, and the poly-TG and TG repeats region in 
exon 9 (Table 1). In this validation study we included mutations that definitely cause CF, as 
defined by the CFTR2 project,1 and some that are classified therein as mutations with 
varying clinical consequences because alleles in the latter category were known to be 
present in the DBS specimens we analyzed.
The NGS library to build CFTR gene amplicon libraries was prepared using MiSeqDx IUO 
CF assay reagents (Illumina) per the manufacturer's instructions. The process started with 
the hybridization of CFTR gene targeted oligonucleotides (probes) to unfragmented genomic 
DNA isolated from DBS. Each probe was also tagged with a common oligonucleotide. DNA 
templates for polymerase chain reaction (PCR) were formed by extending and ligating 80 
targets ranging from 175 to 225 bp DNA fragments. They contained the regions of interest 
and were flanked by the common oligonucleotide sequences that were partially 
complementary to PCR primer sequences. Using indexed primers supplied with the IUO kit, 
the DNA templates then were amplified using PCR to generate the libraries. The indexed 
primers allowed multiplexing of 48 individual DNA samples. Libraries were normalized 
with a magnetic bead–based bind–wash–elute protocol before they were pooled into a single 
tube for sequencing. The sequencing library preparation process is illustrated in Figure 1.
Automated sequencing was accomplished using Illumina's Sequencing by Synthesis 
technology,18 and 48 samples were indexed, normalized, pooled, and loaded onto the 
MiSeqDx reagent cartridge. Data were generated and analyzed with the IUO versions of 
MiSeq Operating Software and Real Time Analysis software. The base calls were generated 
by the IUO versions of the MiSeqDx sequencing system, and MiSeq Reporter software 
performed demultiplexing, alignment, and variant calling. Results from each of the 48 
samples were presented in a text file including assay performance (pass or fail), sample call 
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rate (percentage of successful analyses of targeted regions), status of poly-T and poly-TG 
polymorphisms, detected mutation's name, type, CFTR gene region, genomic location, and 
cDNA and protein names according to Human Genome Variation Society nomenclature.
Sanger sequencing
All CF-causing or varying consequence mutations newly identified by the MiSeqDx Cystic 
Fibrosis System were verified by a traditional Sanger sequencing method performed at the 
Newborn Screening and Molecular Biology Branch at the CDC in Atlanta, GA. The CFTR 
gene was amplified and sequenced using primer sets described in the National Center for 
Biotechnology Information's Probe Database, a public registry of nucleic acid reagents. The 
primer sets (RSS000010013) were previously available as a resequencing assay from 
Applied Biosystems (Grand Island, NY). The RSS000010013 primer sets were used to 
amplify specific target regions identified by NGS using HotStarTaq Master Mix (Qiagen) 
with the following cycling conditions: a 10-min denaturing step at 95 °C, followed by 40 
cycles at 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 1 min, followed by an extension at 72 
°C for 10 min and an indefinite hold at 4 °C. Unused primer and nucleotides were removed 
using ExoSAP-IT (USB Corp., Cleveland, OH), and sequencing was performed using 
BigDye Terminator Ready Reaction kit version 1.1 (Life Technologies). Cycle sequencing 
reactions consisted of 1 μl of PCR product, 1 μl of BigDye Terminator version 1.1, 1.5 μl of 
5× sequencing buffer, and 3.2 pmol of primer. Additional primers for regions not covered by 
the RSS000010013 primer sets were used to characterize the CFTR gene as previously 
described.19 All sequencing reactions were purified using the BigDye XTerminator and 
were electrophoresed with run module BDx_Rapid-Seq36_POP7; data were analyzed using 
SeqScape software (Life Technologies, Grand Island, NY). DNA sequences were aligned 
with GenBank CFTR genomic reference sequence NG_016465.
RESULTS
DBS DNA isolation and NGS assay performance
Successful NGS assay runs were obtained on DNA samples isolated using both Qiagen and 
the laboratory-developed methods. A 100% sample call rate was obtained from 67 DBS 
specimens with 48 distinct known CFTR mutations, and all mutations were 100% 
concordant with previously identified mutations. In the 32 (of 67) specimens with known 
intron 9 poly-T and TG repeat status, there was 100% concordance with previously obtained 
results. The intron 9 poly-T in the tested samples included 5T, 7T, and 9T. The intron 9 TG 
repeat ranged in size from 9 to 13 repeats.
Concordance analysis
NGS assessment of 165 specimens with one CFTR mutation identified through routine NBS 
revealed no additional disease-causing mutations in 156 infants; 151 specimens were 
consistent with their normal sweat chloride test results. In five samples one additional 
disease-causing mutation was found, and the newborn had either an abnormal sweat chloride 
test result (sweat chloride > 30 mmol/l) or was diagnosed with CF or CRMS based on 
additional clinical or genetic evaluations. CFTR mutations with varying consequences were 
identified in four additional specimens; one had an abnormal sweat chloride test result, 
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whereas the other three had normal sweat chloride test results. Of the four CFTR mutations 
with varying consequences, two cases with an F508del/D1152H genotype were labeled 
“carrier” based on the sweat test results and the initial clinical assessment, whereas another 
F508del/D1152H genotype was labeled as CRMS. Note that the D1152H mutation is 
associated with variable clinical consequences. Overall, four of these nine infants with a 
second mutation identified are currently receiving follow-up care as cases of CRMS (Table 
2).
No second disease-causing mutation was found in five specimens that had abnormal sweat 
chloride test results. Three of these five children have been diagnosed with classical CF, and 
the other two have been diagnosed with CRMS. Mutations were identified in two of the five 
samples through the confirmatory testing process during NBS follow-up (Table 3).
Comparison of screening validity measures with routine IRT/DNA and NGS
The PPV of the routine Wisconsin IRT/DNA method evaluating 23 American College of 
Medical Genetics and Genomics–recommended mutations after an IRT analysis was 7.3%. 
When these 165 one-mutation samples were evaluated with the NGS panel (MiSeqDx IUO 
162 mutations/variations), the PPV would have been 77.8% if a positive screen is defined as 
two CF-causing mutations. However, the sensitivity of the IRT/NGS algorithm would have 
decreased as much as 50% for classic CF cases when a positive screen is defined as two CF-
causing mutations because of uncommon mutations found in five patients with classic CF 
that are not included in the MiSeqDx IUO 162 mutations/variations panel.
DISCUSSION
In 2013 the 50-year anniversary of NBS was celebrated and many key developments were 
highlighted, especially those from the past decade. As with most science, advances in 
technology and methodology have generally driven improved screening procedures in public 
health laboratories.20 Discovery of the CFTR gene21 allowed for a second-tier mutation-
detection algorithm3,4 for CF NBS, which greatly increased the sensitivity of the original 
IRT algorithms.22,23 Initially, the two-tier IRT/DNA method incorporated only a single, 
common mutation, F508del (c.1521_1523delCTT), followed later by an expanded panel of 
mutations (typically 23–40 mutations).7,23 These expanded mutation panels add value by 
improving the sensitivity of CF screening, but they remain insufficient and sometimes 
include mutations that are not CF-causing alleles.
Despite its great advantages23–25 and popularity, there are still many challenges with 
IRT/DNA screening, which is now practiced worldwide and is the most widely used 
algorithm for CF NBS.5 One of the biggest challenges is a lower than ideal PPV resulting in 
~10 heterozygote newborn carriers (i.e., a high IRT and single identified CFTR mutation) 
for every CF case diagnosed after follow-up sweat testing. This is exacerbated by the 
occurrence of an insufficient quantity of sweat collected (QNS) and/or indeterminate sweat 
test outcomes in 10–20% of the screen-positive infants. In addition, CFTR panels being used 
have insufficient mutations to allow the detection of minority populations with uncommon 
CF-causing mutations that can cause inequities in NBS, such as M1101K (c.3302T>A), 
more commonly found in Hutterite populations,26 and H199Y (c.595C>T) and S492F (c.
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1475C>T), more commonly found in Hispanic populations. As the genetic diversity of 
populations increases, the current panels used for IRT/DNA screening will not adequately 
meet the need; “missed cases” are more likely among non-Caucasians. In addition, greatly 
expanded CFTR analysis with gene scanning, as done in the California NBS program,27 
rather than targeted mutation analysis with NGS, can lead to the identification of more 
CRMS cases than CF cases, as well as other inconclusive outcomes. Another shortcoming of 
currently used CFTR screening panels is that they also fail to detect class III mutations other 
than G551D (c.1652G>A) that can now be treated effectively by CFTR modulators.28,29
The overall goal of this project was to develop a strategy for improving equity and 
increasing the chance of identifying two CF-causing mutations in infants with CF through 
NBS. The project took advantage of NGS technology combined with the increased 
knowledge about CF-causing mutations determined by the CFTR2 project. The original 
CFTR mutation database identified and described 1,956 mutations/variants in the CFTR 
gene (http://www.genet.sickkids.on.ca/cftr/app, accessed 30 April 2014). The CFTR2 
project, however, which includes assessments of over 40,000 patients, found that only about 
10% are actually CF-causing mutations, providing a major advance in our understanding of 
CF. Combining this new information with advanced molecular technology has allowed us to 
study new screening strategies that may improve follow-up processes.
Our experience of performing an NGS assay using DNA isolated from DBS specimens 
described in this study indicated that those DNA extracts can reliably be used. We showed 
that DNA of sufficient quality could be routinely isolated from DBS not only using a 
multistep method but also using a laboratory-developed one-step method. Our laboratory 
also showed that this simplified one-step DNA isolation method provides sufficient DNA 
for other PCR-based molecular testing applications including real-time quantitative PCR and 
Sanger sequencing (data not shown). The NGS method we used proved to be robust and 
reliable, as evidenced by 100% concordance with the validation of samples representing 48 
distinct CFTR mutations. Further evidence of the robustness of this assay was seen in the 
analysis of the poly-T and TG repeats in intron 9 of CFTR. This complex region contains 
between 9 and 13 TG repeats followed by a homopolymer T region of 5, 7, or 9T. We 
obtained the concordant results on all samples for which this region was previously 
characterized, including samples with two of the same poly-T or TG repeats (i.e., 7T/7T and 
11TG/11TG) and two different poly-T or TG repeats (i.e., 5T/7T and 10TG/11TG).
The NGS assay also allowed us to simultaneously assess 46 patient samples, along with a 
positive and a negative control sample, and to generate auto-call results for the panel of 162 
mutations/variants using the provided software. Although this project focused on the 
validation of NGS in a public health laboratory, our experience suggests that an IRT/NGS 
algorithm can potentially contribute to improved timeliness because nearly all patients with 
CF could be identified genetically from the DBS specimens within one week. When two CF-
causing mutations are detected, the confirmation of a CF diagnosis by sweat testing can be 
routinely achieved within two weeks.9
The CFTR2 project estimated that the inclusion of 139 CFTR mutations should encompass 
97% of known CF-causing mutations.1 However, our data show that even in a region like 
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Wisconsin, with a modest degree of genetic diversity, there are some patients whose second 
mutation is not detected by a 139-mutation panel. Because Wisconsin has genotype data on 
more than 500 patients with CF diagnosed through screening, we sought to understand how 
many CF cases have uncommon mutations not currently on the CFTR2 list; we found the 
five cases reported herein as well as other ones found previously, including G1047R, also 
referred to as 3139 G>C (c.3271G>C), Y849X (c.2679C>A), and 2043delG (c.2043delG). 
These observations stress the need for a more inclusive CF-causing mutation NGS panel to 
achieve a higher sensitivity when it is used for NBS. More than 20 additional CF-causing 
mutations not listed in Table 1 have been added since the initial publication of the CFTR2 
project.1 Fortunately, the MiSeqDx CF sequencing assay already generates sequence 
information that covers these additional CFTR2-listed mutations, and it could be expanded 
using only bioinformatics changes to reveal more mutations as their disease liability is better 
understood.
This study provides evidence that a more inclusive CFTR mutation panel has the potential to 
reduce false-positive results caused by CF heterozygote carrier infants identified using the 
conventional IRT/DNA screening algorithm. As the CFTR2 list of CF-causing mutations 
continues to expand, it is conceivable that the definition of a positive screening test might be 
changed to require the detection of two mutations, particularly if the PPV exceeds 95% with 
an expanded panel of 200 or more CF-causing mutations detected by NGS. The practical 
advantages of using such an expanded panel can clearly be seen in this one year assessment 
comparing traditional IRT/DNA screening in Wisconsin with IRT/NGS, where 151 of 153 
false-positive screens could have been avoided. On the other hand, the NGS method we used 
could be relied on neither to identify “private” mutations nor, given its current technological 
limitations, to be used to detect all the CFTR gross genomic rearrangements such as the 
deletions and duplications that have been described in about 1% of patients with CF.30 If the 
definition of a positive CF NBS test was changed with IRT/NGS to require the detection of 
two CF-causing mutations, the reporting of results to health care providers would need to 
describe these limitations and include an alert similar to that provided for ultrahigh IRT 
levels and a negative DNA tier (sometimes called a “safety net”).
In conclusion, there are many potential advantages of an IRT/NGS screening algorithm. 
These include earlier confirmation of presumptive diagnosis (facilitating expedited initiation 
of therapy even before sweat testing and assessment of pancreatic functional status), more 
equity in diagnosis among ethnic groups that have a lower incidence of F508del and other 
common mutations, and a potential reduction in the number of sweat tests because of the 
extremely low risk of CF in infants with one mutation and in those with ultrahigh IRT 
levels. Moving forward, we are conducting a prospective study using an IRT/NGS model to 
provide evidence of benefits and to identify any new challenges that IRT/NGS may bring to 
NBS for CF.
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Figure 1. Sequencing library generation
Each probe contains two parts of sequences: one for targeting interested CFTR gene regions, 
and another for annealing to polymerase chain reaction (PCR) primers. The DNA templates 
containing targeted CFTR regions were generated by a sequential process consistent with 
hybridization, extension, and ligation. The indexes included in PCR primers allow 
multiplexing of 48 individual DNA samples. The PCR primers also are designed to include 
P5 and P7, which are necessary for initiating sequencing.
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Table 2
Cases with a second mutation detected from the next-generation sequencing panel




Test 1 Test 2
1 64 F508del D110H 71.4 67.1 CF
2 327 F508del Q1313X N/A N/A CF
3 297 F508del Q1313X N/A N/A CF
4 71 R117H (7T) R347H 45.2 41.5
CRMS
b















c 11 QNS Carrier
9 176 F508del
D1152H
c 24 26 Carrier
CF, cystic fibrosis; CRMS, CFTR-related metabolic syndrome; IRT, immunoreactive trypsinogen; QNS, quantity not sufficient.
a
Clinical assessments listed were the reported diagnoses made by CF specialists who evaluated these infants according to the clinical, newborn 
screening, and genetic nformation available during the follow-up processes.
b
Current diagnosis, as followed up by CF clinics.
c
Mutation with varying consequences.
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Table 3
Affected cases without the second mutation detected from the next-generation sequencing panel
Case no. IRT (ng/ml) Second-tier DNA
Sweat chloride (mmol/l)
Clinical assessment Additional information
Test 1 Test 2
1 237 F508del 134.1 Quantity not sufficient CF —
2 102 2789 + 5G>A 56.3 53.7 CRMS c.2909-15T>G identified by DNA 
sequencing
3 101 N1303K 79 75 CF No CFTR gene deletion was 
identified by Multiplex ligation-
dependent probe amplification
4 144 F508del 100 87 CF G480D identified by DNA 
sequencing
5 58 F508del 55.2 55.1 CRMS —
CF, cystic fibrosis; CRMS, CFTR-related metabolic syndrome; IRT, immunoreactive trypsinogen.
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